



Executive

Headquarters

Department of
Health

Quarry House

Quarry Hill

Leeds LS2 7UE

Tel 0113 254 5000

To: NHS Trust Medical Directors

cc: NHS Trust Chief Executives
Health Authority Chief Executives

6 February 1998

PL (CO) (98) 1

Dear Colleague,

NEW VARIANT CJD - PATIENTS WHO HAVE RECEIVED IMPLICATED BLOOD PRODUCTS

In September 1997 the Chief Medical Officer announced that the use made of blood donated by persons who had subsequently developed new variant Creutzfeld Jacob disease (nvCJD) would be traced and, as a purely precautionary measure, any unused blood components or products withdrawn. As a consequence, there have been a number of recall exercises over recent months, the latest being the batch of Amerscan Pulmonate Two which was withdrawn in December.

A number of clinicians and Trusts affected by these recall exercises have contacted the Department of Health to ask for the Department's view on what patients who have received nvCJD-implicated blood components or products should be told. This raises some very difficult issues on which the Department has taken expert ethical advice. I thought it might be helpful to set out that advice.

The advice which the Department has received from ethics experts and other advisory bodies is that there is no need to inform patients because:

- i. it is thought unlikely that nvCJD will be transmitted in this way;
- ii. there is no diagnostic test for nvCJD;
- iii. even if a test was available, there is no preventative treatment that could be offered.

In these circumstances the general view is that patients will not benefit from this knowledge, and that uncertainty created by informing patients could have the contrary effect causing unjustified worry and creating a permanent blight on their lives in relation, for example, to obtaining life or health care insurance.